Literature DB >> 10928383

Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals.

O C Boerman1, W J Oyen, F H Corstens.   

Abstract

Radio-labeled receptor-binding peptides have emerged as an important class of radiopharmaceuticals. In vertebrates, these peptides transmit their biological function by binding to their specific receptor on the target cell surface. This specific receptor-binding property is exploited when the radio-labeled peptide is used as a radiopharmaceutical. The high-binding affinity for its receptor facilitates retention of the peptide in receptor-expressing tissues, whereas its relatively small size facilitates rapid clearance from the blood and other nontarget tissues. Receptor-binding peptides labeled with gamma-emitters can be used to visualize receptor-positive cells in vivo. In addition, when labeled with beta- or alpha-emitters, these peptides can be used for peptide-receptor radionuclide therapy. Various receptors are overexpressed on particular tumor types, and peptides binding to these receptors can be used to visualize tumor lesions scintigraphically. Furthermore, peptides binding receptors on granulocytes can be used to image infectious and inflammatory foci, whereas peptides binding receptors on activated thrombocytes can be used for thrombus imaging. Here, the peptide analogs that are under development for these applications are reviewed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928383     DOI: 10.1053/snuc.2000.7441

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  8 in total

1.  The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.

Authors:  A Nikolaou; D Thomas; C Kampanellou; K Alexandraki; L G Andersson; A Sundin; G Kaltsas
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

Review 2.  Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature.

Authors:  Sofiane Maza; Uwe Trefzer; Maja Hofmann; Silke Schneider; Christiane Voit; Thomas Krössin; Andreas Zander; Heike Audring; Wolfram Sterry; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-24       Impact factor: 9.236

Review 3.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

Review 4.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

Review 5.  Arsenic trioxide: insights into its evolution to an anticancer agent.

Authors:  Maneka Hoonjan; Vaibhav Jadhav; Purvi Bhatt
Journal:  J Biol Inorg Chem       Date:  2018-02-02       Impact factor: 3.358

6.  Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT.

Authors:  Yang Zhou; Sudipta Chakraborty; Shuang Liu
Journal:  Theranostics       Date:  2011-01-18       Impact factor: 11.556

7.  Nuclear medicine imaging and therapy of neuroendocrine tumours.

Authors:  Martin Gotthardt; Ingrid Dijkgraaf; Otto C Boerman; Wim J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

8.  Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma.

Authors:  I Al Jammaz; B Al-Otaibi; Y Al-Malki; A Abousekhrah; S M Okarvi
Journal:  EJNMMI Radiopharm Chem       Date:  2021-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.